Stockscreener 앱 받기
0.782
1.23%
0.0095
시간 외 거래:
.78
-0.002
-0.26%
전일 마감가:
$0.7725
열려 있는:
$0.77
하루 거래량:
2.61M
Relative Volume:
0.58
시가총액:
$169.69M
수익:
-
순이익/손실:
$-90.60M
주가수익비율:
-1.2476
EPS:
-0.6268
순현금흐름:
$-68.88M
1주 성능:
-0.70%
1개월 성능:
+16.33%
6개월 성능:
-42.50%
1년 성능:
+81.69%
1일 변동 폭
$0.76
$0.8173
1주일 범위
$0.76
$0.8242
52주 변동 폭
$0.4253
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.782 | 167.63M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-10 | 개시 | William Blair | Outperform |
| 2023-11-30 | 개시 | Leerink Partners | Outperform |
| 2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
What do we know so far from TN-201 trial? - Moomoo
TN-201 and TN-401 - Moomoo
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com South Africa
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com Canada
Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements - Sahm
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Raises Target Price to $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Presents at Heart Failure 2026Slideshow (NASDAQ:TNYA) 2026-05-15 - Seeking Alpha
Chardan Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Tenaya Shares Rise on Positive Data From ARVC Study - Moomoo
Transcript : Tenaya Therapeutics, Inc.Special Call - marketscreener.com
Positive interim data from cohorts 1 and 2 of Tenaya's Ridge-1 phase 1b/2 clinical trial of TN-401 - marketscreener.com
Tenaya Therapeutics presents new RIDGE-1 trial results showing arrhythmia reduction in PKP2-associated ARVC - Traders Union
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC - The Manila Times
Tenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical Trial - Quiver Quantitative
Tenaya reports interim gene therapy trial results for heart condition - Investing.com
Early TN-401 gene therapy trial eases dangerous heart rhythms - Stock Titan
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - MSN
TNYA.O Technical Analysis & Stock Price Forecast - Intellectia AI
Tenaya Therapeutics partners on parent attitudes survey for gene therapy in pediatric cardiomyopathy - Traders Union
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Moomoo
Eugene Braunwald legacy in HCM research honored by Tenaya Therapeutics - Traders Union
Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed? - Yahoo Finance
TradingKey - TradingKey
Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts - simplywall.st
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tenaya Therapeutics Inc 주식 (TNYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
May 18 '26 |
Sale |
0.79 |
3,121 |
2,477 |
215,497 |
| Higa Tomohiro | SVP, Finance |
May 18 '26 |
Sale |
0.79 |
1,485 |
1,178 |
118,267 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 25 '26 |
Sale |
0.56 |
3,511,826 |
1,975,051 |
0 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 24 '26 |
Sale |
0.62 |
658,440 |
405,138 |
1,649,281 |
0.98%
0.12%
자본화:
|
볼륨(24시간):